Terms: = Breast cancer AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1
609 results:
1. The atr inhibition by Elimusertib enhances the radiosensitivity of MDA-MB-231 triple negative breast cancer in vitro.
Guney Eskiler G; Halis H; Hamarat KF; Derlioglu RR; Ugurlu BT; Haciefendi A
Int J Radiat Biol; 2024; 100(5):715-723. PubMed ID: 38421209
[TBL] [Abstract] [Full Text] [Related]
2. Blocking LBH expression causes replication stress and sensitizes triple-negative breast cancer cells to atr inhibitor treatment.
Garikapati K; Young IC; Hong S; Rai P; Jain C; Briegel KJ
Oncogene; 2024 Mar; 43(12):851-865. PubMed ID: 38297083
[TBL] [Abstract] [Full Text] [Related]
3. Piperlongumine inhibits antioxidant enzymes, increases ROS levels, induces DNA damage and G2/M cell cycle arrest in breast cell lines.
Baranoski A; Semprebon SC; Biazi BI; Zanetti TA; Corveloni AC; Areal Marques L; Lepri SR; Coatti GC; Mantovani MS
J Toxicol Environ Health A; 2024 Apr; 87(7):294-309. PubMed ID: 38279841
[TBL] [Abstract] [Full Text] [Related]
4. Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.
Mahlow J; Barry M; Albertson DJ; Jo YJ; Balatico M; Seasor T; Gebrael G; Kumar SA; Sayegh N; Tripathi N; Agarwal N; Swami U; Sirohi D
Hum Pathol; 2024 Feb; 144():28-33. PubMed ID: 38278448
[TBL] [Abstract] [Full Text] [Related]
5. Construction and validation of a prognostic nutritional index-based nomogram for predicting pathological complete response in breast cancer: a two-center study of 1,170 patients.
Qu F; Luo Y; Peng Y; Yu H; Sun L; Liu S; Zeng X
Front Immunol; 2023; 14():1335546. PubMed ID: 38274836
[TBL] [Abstract] [Full Text] [Related]
6. The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative breast cancers.
Aguilar-Mahecha A; Alirezaie N; Lafleur J; Bareke E; Przybytkowski E; Lan C; Cavallone L; Salem M; Pelmus M; Aleynikova O; Greenwood C; Lovato A; Ferrario C; Boileau JF; Mihalcioiu C; Roy JA; Marcus E; Discepola F; Majewski J; Basik M
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38254917
[TBL] [Abstract] [Full Text] [Related]
7. Towards Understanding the Development of breast cancer: The Role of RhoJ in the Obesity Microenvironment.
Bou Malhab LJ; Nair VA; Qaisar R; Pintus G; Abdel-Rahman WM
Cells; 2024 Jan; 13(2):. PubMed ID: 38247865
[TBL] [Abstract] [Full Text] [Related]
8. Targeted delivery and apoptosis induction of CDK-4/6 inhibitor loaded folic acid decorated lipid-polymer hybrid nanoparticles in breast cancer cells.
Rajana N; Sandeep Chary P; Bhavana V; Deshmukh R; Dukka K; Sharma A; Kumar Mehra N
Int J Pharm; 2024 Feb; 651():123787. PubMed ID: 38184023
[TBL] [Abstract] [Full Text] [Related]
9. CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method.
Javed SR; Lord S; El Badri S; Harman R; Holmes J; Kamzi F; Maughan T; McIntosh D; Mukherjee S; Ooms A; Radhakrishna G; Shaw P; Hawkins MA
Br J Cancer; 2024 Feb; 130(3):467-475. PubMed ID: 38129525
[TBL] [Abstract] [Full Text] [Related]
10. The impact of metabolic syndrome in breast reconstruction decision-making and postoperative outcomes: A nationwide analysis.
Escobar-Domingo MJ; Bustos VP; Kim EJ; Campbell T; Fanning JE; Foppiani JA; Merle C; Lin SJ; Lee BT
J Plast Reconstr Aesthet Surg; 2024 Feb; 89():21-29. PubMed ID: 38128370
[TBL] [Abstract] [Full Text] [Related]
11. PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition.
Li Y; Dobrolecki LE; Sallas C; Zhang X; Kerr TD; Bisht D; Wang Y; Awasthi S; Kaundal B; Wu S; Peng W; Mendillo ML; Lu Y; Jeter CR; Peng G; Liu J; Westin SN; Sood AK; Lewis MT; Das J; Yi SS; Bedford MT; McGrail DJ; Sahni N
Cell Rep Med; 2023 Dec; 4(12):101326. PubMed ID: 38118413
[TBL] [Abstract] [Full Text] [Related]
12. Design, development, and evaluation of CDK-4/6 inhibitor loaded 4-carboxy phenyl boronic acid conjugated pH-sensitive chitosan lecithin nanoparticles in the management of breast cancer.
Pooja YS; Rajana N; Yadav R; Naraharisetti LT; Godugu C; Mehra NK
Int J Biol Macromol; 2024 Feb; 258(Pt 1):128821. PubMed ID: 38110163
[TBL] [Abstract] [Full Text] [Related]
13. Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib.
Rosen E; Yap TA; Lee EK; Højgaard M; Mettu NB; Lheureux S; Carneiro BA; Plummer R; Fretland AJ; Ulanet D; Xu Y; McDougall R; Koehler M; Fontana E
Clin Cancer Res; 2024 Feb; 30(4):687-694. PubMed ID: 38078898
[TBL] [Abstract] [Full Text] [Related]
14. [Work Participation after Multimodal Rehabilitation due to cancer: Representative Analyses using Routine Data of the German Pension Insurance].
Fauser D; Zollmann P; Streibelt M; Bethge M
Rehabilitation (Stuttg); 2024 Apr; 63(2):107-118. PubMed ID: 38065547
[TBL] [Abstract] [Full Text] [Related]
15. Programmable DNA Hydrogel Assisting Microcrystal Formulations for Sustained Locoregional Drug Delivery in Surgical Residual Tumor Lesions and Lymph Node Metastasis.
Zhang ZJ; Zhou Y; Tong H; Sun XC; Lv ZC; Yong JK; Wu YC; Xiang XL; Ding F; Zuo XL; Li F; Xia Q; Feng H; Fan CH
Adv Healthc Mater; 2024 Apr; 13(11):e2303762. PubMed ID: 38047767
[TBL] [Abstract] [Full Text] [Related]
16. Comparison effects of Ferula gummosa essential oil and Beta-pinene Alginate nanoparticles on human melanoma and breast cancer cells proliferation and apoptotic index in short term normobaric hyperoxic model.
Osanloo M; Pishamad S; Ghanbariasad A; Zarenezhad E; Alipanah M; Alipanah H
BMC Complement Med Ther; 2023 Nov; 23(1):428. PubMed ID: 38017466
[TBL] [Abstract] [Full Text] [Related]
17. Association of Germline Variation in Driver Genes with breast cancer Risk in Chilean Population.
Morales-Pison S; Tapia JC; Morales-González S; Maldonado E; Acuña M; Calaf GM; Jara L
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003265
[TBL] [Abstract] [Full Text] [Related]
18. Development of PARP Inhibitors in Targeting Castration-Resistant Prostate cancer.
Mouw KW; Choudhury AD
Cancer Treat Res; 2023; 186():103-124. PubMed ID: 37978133
[TBL] [Abstract] [Full Text] [Related]
19. Mechanisms of PARP Inhibitor Resistance.
O'Connor MJ; Forment JV
Cancer Treat Res; 2023; 186():25-42. PubMed ID: 37978129
[TBL] [Abstract] [Full Text] [Related]
20. Mitochondriotropic agents conjugated with NSAIDs through metal ions against breast cancer cells.
Banti CN; Piperoudi AA; Raptopoulou CP; Psycharis V; Athanassopoulos CM; Hadjikakou SK
J Inorg Biochem; 2024 Jan; 250():112420. PubMed ID: 37918185
[TBL] [Abstract] [Full Text] [Related]
[Next]
